GDF15 Specific Neutra™ Antibody Products
Product listStruggling with prolonged drug development or challenges in addressing cancer cachexia and immunosuppression? Creative Biolabs' GDF15 specific Neutra™ antibodies employ advanced monoclonal technologies to accelerate therapeutic discovery and deliver precision targeting for metabolic and oncologic disorders.
Introduction to GDF15
Growth Differentiation Factor 15 (GDF15), a divergent member of the TGF-β superfamily, is a stress-responsive cytokine that functions as a key regulator of systemic energy balance and immune modulation. Under normal physiological conditions, GDF15 expression remains low but is markedly upregulated in pathologies such as cancer, inflammatory disorders, and metabolic diseases.
Fig.1 Activation of GDF15 and its action.1
- Structure
GDF15 is synthesized as a precursor protein comprising a signal peptide, propeptide domain, and a mature C-terminal region. Proteolytic cleavage releases the mature 25 kDa homodimer stabilized by interchain disulfide bonds. Unique among TGF-β members, GDF15 features a conserved cysteine-knot structure critical for receptor binding. Cryo-EM studies reveal that its tertiary configuration enables selective interaction with the GDNF family receptor α-like (GFRAL), the primary receptor mediating its metabolic effects.
- Related Signaling Pathways
GDF15 operates through the GFRAL-RET co-receptor complex, activating downstream signaling cascades such as AKT and ERK to suppress appetite and modulate energy expenditure. It also intersects with p53 and HIF-1α pathways, linking cellular stress responses to systemic metabolic adaptations. Overexpression of GDF15 in tumors correlates with immunosuppression, driven by its ability to inhibit CD8+ T-cell activity and promote regulatory T-cell infiltration.
- Associated Pathologies
Elevated GDF15 levels are hallmark features of cancer cachexia, a debilitating syndrome characterized by progressive weight loss and muscle atrophy. It is also implicated in hepatocellular carcinoma, non-small cell lung cancer, and inflammatory bowel disease, where it exacerbates immune evasion and disease progression.
Applications of Anti-GDF15 Neutralizing Antibodies
- Enhancing Anti-PD-1/PD-L1 Therapy in Solid Tumors
GDF15 neutralization overcomes resistance to immune checkpoint inhibitors by revitalizing T-cell-mediated tumor clearance. Clinical trials demonstrate synergistic effects when combined with anti-PD-1 agents, significantly improving response rates in refractory cancers.
- Reversing Cancer Cachexia
By antagonizing GDF15's catabolic effects, these antibodies restore muscle mass and physical function in cachexia models. Subcutaneous administration in preclinical studies mitigates weight loss and improves survival outcomes.
- Targeting Hepatocellular Carcinoma
Anti-GDF15 antibodies reduce tumor burden in murine liver cancer models by reprogramming the immunosuppressive microenvironment, decreasing Treg infiltration, and bolstering CD8+ T-cell cytotoxicity.
- Combination Therapies with CD40 or Other Inhibitors
Co-administration with CD40 agonists or chemotherapy enhances anti-tumor efficacy, offering a multi-pronged strategy to address complex malignancies.
- Diagnostic and Prognostic Biomarker Applications
GDF15 levels serve as a prognostic indicator for disease severity and treatment response, enabling personalized therapeutic strategies.
Our Anti-GDF15 Antibodies
Creative Biolabs' neutralizing antibodies target GDF15 with high affinity, blocking its interaction with GFRAL to restore metabolic balance and counteract immune suppression. Engineered using hybridoma platforms, these antibodies demonstrate cross-species reactivity and superior pharmacokinetics. For instance, preclinical studies highlight their efficacy in reversing cachexia-associated weight loss and enhancing anti-tumor immunity by reactivating CD8+ T-cell responses.
Creative Biolabs' GDF15-specific antibodies are engineered for exceptional specificity and translational impact, supporting breakthroughs in cachexia management, immunotherapy, and combination therapies.
Contact our scientific team today to explore tailored solutions for your research or therapeutic development.
REFERENCE
- Babalghith, Ahmad O., et al. "The potential role of growth differentiation factor 15 in COVID-19: a corollary subjective effect or not?." Diagnostics 12.9 (2022): 2051. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/diagnostics12092051
